ClinicalTrials.gg
Active, not recruitingNCT06818812Updated Aug 25, 2026

A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

A Phase 1 interventional study of INCB186748 and Cetuximab in Solid Tumors, sponsored by Incyte Corporation. Active, not recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies in Colorectal Neoplasms by Incyte Corporation — 3 open to participants now, 5 under way, 1 of them phase 3. Colorectal Neoplasms · Incyte Corporation.

Enrollment
15th of 19
30 · median 70
Started
2025
the only one that year
Phase 1
8 of 19
1 open now
Registered
17th of 19
by date

Among the 19 studies in Colorectal Neoplasms by Incyte Corporation, this one is the 15th largest by enrollment, is the only one that started in 2025, is one of 8 in phase 1, and was the 17th registered.

Colorectal Neoplasms

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

3 of the 19 studies in Colorectal Neoplasms by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Colorectal Neoplasms by Incyte Corporation, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation.

03

Conditions studied

  • Solid Tumors

Keywords

  • INCB186748
  • KRASG12D Mutation
  • pancreatic ductal adenocarcinoma (PDAC)
  • colorectal cancer (CRC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years old.
  • Locally advanced or solid tumor with KRAS G12D mutation.
  • For Part 1 and Part 2 Combination Group 1: Disease progression on or after prior standard treatment, or intolerance to or ineligibility for standard treatment, or no standard available treatment to improve the disease outcome.
  • For Part 2 Combination Groups 2 and 3: No more than 1 prior standard treatment.
  • Cohort-specific requirements as follows:

    • Parts 1a and 1d: or cytologically confirmed malignant solid tumor of any tissue origin.
    • Part 1b

      • Disease Group 1: diagnosis of PDAC and at least 1 but no more than 2 prior standard systemic regimens for pancreatic cancer.
      • Disease Group 2: diagnosis of CRC.
    • Part 1c: Confirmed diagnosis of PDAC or CRC.
    • Parts 2a and 2b

      • Combination Group 1 (INCB186748 in combination with cetuximab):

        • Diagnosis of PDAC or
        • Diagnosis of CRC and ∘ Prior treatment in the advanced setting with a fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan and

          • In Part 2a: ≤ 3 prior standard regimens.
          • In Part 2b: ≤ 2 prior standard regimens.
      • Combination Group 2 (INCB186748 in combination with GEMNabP) and
      • Combination Group 3 (INCB186748 in combination with mFOLFIRINOX):

        • Diagnosis of PDAC.
        • ≤ 1 prior standard systemic regimen for pancreatic cancer.
  • according to v1.1.
  • performance status score of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any KRAS inhibitor.
  • Known additional invasive within 1 year of the first dose of study drug.
  • History of organ transplant, including stem cell transplantation.
  • Significant, uncontrolled medical condition.
  • History or presence of an abnormality.
  • Inadequate organ function.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Part 1a: Dose Escalation monotherapy

    INCB186748 at the protocol-defined dose strength based on cohort assignment.

    Drug: INCB186748

  • Experimental
    Part 1b: Dose Expansion monotherapy

    INCB186748 at the protocol-defined dose strength based on cohort assignment.

    Drug: INCB186748

  • Experimental
    Part 1c: Pharmacodynamic cohort

    INCB186748 at the protocol-defined dose strength based on cohort assignment.

    Drug: INCB186748

  • Experimental
    Part 1d: Food-Effect

    Evaluate food effect on drug exposure as defined in the protocol.

    Drug: INCB186748

  • Experimental
    Part 2a: Dose Escalation combination

    INCB186748 in combination at the protocol-defined dose strength based on cohort assignment.

    Drug: INCB186748 · Drug: Cetuximab · Drug: GEMNabP · Drug: mFOLFIRINOX

  • Experimental
    Part 2b: Dose Expansion combination

    INCB186748 in combination at the protocol-defined dose strength based on cohort assignment.

    Drug: INCB186748 · Drug: Cetuximab · Drug: GEMNabP · Drug: mFOLFIRINOX

Interventions

  • DrugINCB186748

    INCB186748 will be administered at protocol defined dose.

  • Cetuximab will be administered at protocol defined dose.

  • DrugGEMNabP

    GEMNabP will be administered at protocol defined dose.

  • DrugmFOLFIRINOX

    mFOLFIRINOX will be administered at protocol defined dose.

06

What researchers measure

Primary outcomes

  1. Number of participants with Dose Limiting Toxicities (DLTs)

    Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol.

    Time frame: Up to 28 days

  2. Number of participants with Treatment-emergent Adverse Events (TEAEs)

    Defined as adverse events reported for the first time or worsening of a pre-existing event occurring after the first dose of study drug up to 30 days (for INCB186748 as monotherapy and in combination with GEMNabP or mFOLFIRINOX) and 60 days (for INCB186748 in combination with cetuximab) after the last dose of INCB186748.

    Time frame: Up to approximately 12 months and 60 days

  3. Number of participants with TEAEs leading to dose modification or discontinuation

    Number of participants with TEAEs leading to dose modification or discontinuation.

    Time frame: Up to approximately 12 months and 60 days

Secondary outcomes

  1. INCB186748 pharmacokinetic (PK) in Plasma

    INCB186748 concentration in plasma.

    Time frame: Up to approximately 12 months

  2. Objective Response Rate (ORR)

    Defined as having a best overall Complete Response (CR) or Partial Response (PR), as determined by the investigator by radiographic disease assessment according to RECIST v1.1.

    Time frame: Up to approximately 12 months

  3. Disease Control Response (DCR)

    Defined as having a best overall response of CR, PR, or Stable Disease (SD) as determined by the investigator by radiographic disease assessment according to RECIST v1.1.

    Time frame: Up to approximately 12 months

  4. Duration of Response (DOR)

    Defined as the time from earliest date of disease response (Completed Response or Partial Response) until earliest date of disease progression as determined by the investigator by radiographic disease assessment according to RECIST v1.1 or death due to any cause if occurring sooner than progression.

    Time frame: Up to approximately 12 months

07

Study locations

9 sites
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.

Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's planned 24 months is below that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2025
First posted
Feb 10, 2025
StartActual
Mar 27, 2025
Primary completionEst.
Mar 27, 2027
CompletionEst.
Mar 27, 2027
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06818812
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Feb 10, 2025
Start date
Mar 27, 2025
Primary completion
Mar 27, 2027 (estimated)
Completion
Mar 27, 2027 (estimated)
Last update
Aug 25, 2026

Study contacts

Incyte Medical Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion